A Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Axial Spondyloarthritis

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Axial Spondyloarthritis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2015

At a glance

  • Drugs Brodalumab (Primary)
  • Indications Spondylarthritis
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 18 Jun 2015 Status changed from not yet recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 05 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top